Drug intelligence / Profile preview

KD-412

Development stage: Unknown
Lead developer: Meiji
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

KD-412, commercially known as BOVISUNT AKABANE, is an inactivated veterinary vaccine developed by KM Biologics (a subsidiary of Meiji Holdings) for the prevention of Akabane disease in cattle. Akabane disease is a viral infection transmitted by biting midges (Culicoides) that causes congenital abnormalities, abortions, and stillbirths in ruminants. The vaccine functions by inducing protective immunity and neutralizing antibodies against the Akabane virus, thereby preventing transplacental infection and reproductive failure in cattle populations. It is currently approved and launched for use in Japan.

Brand names: BOVISUNT AKABANE
Other names: Akabane disease vaccineAkabane virus vaccine

Targets

BCR (Bovine B-cell receptor)Gc (Akabane virus envelope glycoprotein Gc)Gn (Akabane virus envelope glycoprotein Gn)

Beyond the preview

Go deeper on KD-412.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KD-412.

Explore the full profile